Ƶ

Digital Therapies Compared; Summertime Sadness? Spravato Monotherapy Under Review

— News and commentary from the psychiatry world

Ƶ MedicalToday
Illustration of a brain shaped maze.

Three different , including SilverCloud and Headspace, showed generally similar improvements in depressive and anxiety symptoms after 6 weeks in a randomized clinical trial. (JAMA Network Open)

Can happen in the summer, too? (The Hill)

Among nursing home residents, CYP2D6-metabolized opioids used with -- like fluoxetine (Prozac) and bupropion (Wellbutrin) -- were associated with worsening pain compared with CYP2D6-neutral antidepressants. (Annals of Internal Medicine)

Intravenous ketamine given for 3 consecutive days did not produce a noticeable advantage in compared with active placebo midazolam, according to a pilot study of people with treatment-resistant depression in Thailand. (BMC Psychiatry)

Johnson & Johnson (Spravato) for FDA approval as a monotherapy for adults with treatment-resistant depression. It's currently approved in combination with an oral antidepressant for depression with acute suicidal ideation or behavior.

Here's how one spurred a new art movement. (New York Times)

Community-level wasn't linked with clinical diagnoses of generalized anxiety or major depressive disorder, but was tied with a higher prevalence of schizophrenia spectrum disorder, stimulant use disorder, and opioid use disorder. (JAMA Psychiatry)

Should be fully integrated into healthcare systems, including primary care practices and hospitals? (STAT)

Several mushroom gummy brands marketed as were found to contain illegal hallucinogens such as psilocybin. (Morbidity and Mortality Weekly Report)

Meanwhile, a study in Nature suggested that by disrupting certain brain networks and temporarily increases brain plasticity.

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.